Insider Selling: National Research Co. (NASDAQ:NRC) President Sells $158,000.00 in Stock

Share on StockTwits

National Research Co. (NASDAQ:NRC) President Steven D. Jackson sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $63.20, for a total value of $158,000.00.

National Research stock opened at $59.29 on Friday. The stock has a market capitalization of $1.57 billion, a PE ratio of 57.01 and a beta of 0.82. National Research Co. has a 12 month low of $35.58 and a 12 month high of $68.86. The business has a 50 day simple moving average of $58.08 and a 200-day simple moving average of $38.73. The company has a debt-to-equity ratio of 1.24, a current ratio of 0.62 and a quick ratio of 0.62.

National Research (NASDAQ:NRC) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.29 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.03. The business had revenue of $31.41 million during the quarter, compared to analysts’ expectations of $30.26 million. National Research had a return on equity of 124.11% and a net margin of 24.59%.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Monday, September 30th will be given a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date of this dividend is Friday, September 27th. National Research’s dividend payout ratio (DPR) is presently 73.08%.

Several institutional investors have recently bought and sold shares of the company. Royal Bank of Canada boosted its stake in National Research by 13.1% during the second quarter. Royal Bank of Canada now owns 15,051 shares of the company’s stock worth $866,000 after buying an additional 1,749 shares during the last quarter. Susquehanna International Group LLP acquired a new position in shares of National Research in the 2nd quarter valued at $249,000. Nuveen Asset Management LLC acquired a new position in shares of National Research in the 2nd quarter valued at $2,920,000. Citadel Advisors LLC lifted its stake in shares of National Research by 123.9% in the 2nd quarter. Citadel Advisors LLC now owns 14,718 shares of the company’s stock valued at $848,000 after purchasing an additional 8,144 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. acquired a new position in shares of National Research in the 2nd quarter valued at $228,000. Institutional investors and hedge funds own 36.03% of the company’s stock.

About National Research

National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement.

Featured Article: What does a hold rating mean?

Insider Buying and Selling by Quarter for National Research (NASDAQ:NRC)

Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Aptevo Therapeutics Inc Expected to Post Q1 2021 Earnings of  Per Share
Aptevo Therapeutics Inc Expected to Post Q1 2021 Earnings of Per Share
Virtus Health  Stock Price Down 0.5%
Virtus Health Stock Price Down 0.5%
Globalworth Real Estate Investments  Trading 5.1% Higher
Globalworth Real Estate Investments Trading 5.1% Higher
Panoramic Resources  Trading Up 1.2%
Panoramic Resources Trading Up 1.2%
Audentes Therapeutics Inc Forecasted to Post Q1 2021 Earnings of  Per Share
Audentes Therapeutics Inc Forecasted to Post Q1 2021 Earnings of Per Share
Radware Ltd. Expected to Post Q1 2021 Earnings of $0.18 Per Share
Radware Ltd. Expected to Post Q1 2021 Earnings of $0.18 Per Share


 
© 2006-2019 Zolmax.